Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04090463 Suspended - Clinical trials for Borderline Resectable Pancreatic Cancer

IORT on Borderline Resectable Pancreatic Cancer

PancFORT
Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after FOLOFIRINOX-base chemotherapy, and SBRT, increases the 3-year survival rate. A total of 101 patients will be enrolled, and these patients will receive IORT of 10 to 20 Gy, according to the resection status (to the tumor bed after resection, or to the tumor in situ in case of non-resection).

NCT ID: NCT04084158 Suspended - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Start date: September 7, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of Toripalimab injection (JS001) given before and after concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

NCT ID: NCT04069572 Suspended - Chronic Pain Clinical Trials

Vibratory Stimulation for the Treatment of Chronic Pain

Start date: September 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to perform a first in man study with VCR stimulation of the belly and back for patients with chronic pain conditions including pelvic pain, functional abdominal pain, or low back pain. This study will also examine VCR stimulation of the temporal region for patients with migraine with or without aura. Additional goals of the study will be to determine the safety, tolerability, and acceptability of VCR stimulation for the treatment of these pain conditions.

NCT ID: NCT04066660 Suspended - Clinical trials for Advanced Hepatocellular Carcinoma

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with metastatic colorectal cancer. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

NCT ID: NCT04066478 Suspended - Infertility, Female Clinical Trials

Does DHEA IVF Outcomes in Poor Responders?

DHEA
Start date: October 8, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a RCT to examine whether DHEA is capable of improving results for poor responders to ovarian stimulation during IVF treatment

NCT ID: NCT04060849 Suspended - Clinical trials for Malignant Solid Neoplasm

Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Start date: September 3, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.

NCT ID: NCT04053062 Suspended - Clinical trials for Castrate-Resistant Prostate Cancer

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Start date: July 16, 2020
Phase: Phase 1
Study type: Interventional

This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with CRPC.

NCT ID: NCT04038424 Suspended - Clinical trials for Ischemic Stroke and Hemorrhagic Stroke

The Effect of Art Therapy on Patients With Stroke

Start date: September 20, 2019
Phase: N/A
Study type: Interventional

Stroke can affect the physical, emotional and social aspects of the patient and their family members. It is the main cause of complex disability, with a high number of people living with its effects. Stroke can result in impairments in motor function, language, cognition, sensory processing, cognition, and emotional disturbances, which can affect the performance of functional activities and mental health status. Getting patients involved in art therapy (AT) class has shown to alleviate stress and promote a sense of wellbeing, which can aid their recovery and rehabilitation. The benefits of art therapy for people living with different health conditions worldwide have been reported, however, its effect on Egyptian patients with stroke has been neglected.

NCT ID: NCT04037254 Suspended - Clinical trials for Prostate Adenocarcinoma

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

NADIR
Start date: June 3, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.

NCT ID: NCT04026516 Suspended - Clinical trials for Benign Paroxysmal Positional Vertigo

CAVA: Dizziness Trial

CAVA
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Clinical investigation of a medical device (CAVA) for recording eye movements. Patients suffering from diagnosed dizziness conditions will wear the device for 23 hours a day, for 30 days. The device will capture normal eye movement data as well as data corresponding to any dizzy events experienced. At the end of the trial, the data will be downloaded and a scientist will perform a blinded analysis of the data. Specifically, they will attempt to identify the dates on which dizziness was reported.